英国临床医学肿瘤学杂志,卡博替尼184:卡博替尼,末期肾肿瘤又一个规范医治药品

  • A+
所属分类:资讯

英国临床医学肿瘤学杂志,卡博替尼184:卡博替尼,末期肾肿瘤又一个规范医治药品 。
摘 要:卡博替尼是什么药。英国临床医学肿瘤学杂志,卡博替尼184:卡博替尼,末期肾肿瘤又一个规范医治药品英国《临床肿瘤学杂志》2022年1月8日线上先给

卡博替尼是晚中后期肾细胞癌伴骨转移的情况蔓延病患者医治的一个新标准吗?METEOR实验亚组分析

目地卡博替尼是一种酪氨酸激酶缓聚剂,对包含MET、毛细血管内皮细胞细胞生长因子蛋白激酶和AXL英国临床医学肿瘤学杂志,卡博替尼184:卡博替尼,末期肾肿瘤又一个规范医治药品以内的酪氨酸激酶有抑制效果,在METEOR III期实验中,卡博替尼提升了以往毛细血管内皮细胞细胞生长因子蛋白激酶靶向药物治疗后的晚中后期肾细胞癌病患者的无进度存活時间(PFS)、总存活時间(OS)和客观缓解率(ORR)。因为骨转移的情况蔓延与肾细胞癌病患者一并产生的异常病症升高相关,因而在METEOR该实验中剖析了骨有关結果。病患者与方式 将658例病患者按1:1任意分派,各自接纳卡博替尼 60mg或依维莫司10mg。依照单独的放射学联合会判断的入组时的骨转移的情况蔓延情况开展亚成分组,对病患者的PFS、OS和ORR开展预先确定的亚组分析。其他科学研究终点站包含依照单独的放射学联合会判断的骨扫描减轻状况、人体骨骼有关(过虑词)及英国临床医学肿瘤学杂志,卡博替尼184:卡博替尼,末期肾肿瘤又一个规范医治药品骨生物标志物转变。結果 针对入组时有骨转移的情况蔓延的病患者(卡博替尼组 [n=77],依维莫司组[n=65]),卡博替尼组负相关PFS为7.4个月,依维莫司组2.7个月(风险之比0.33[95%CI,0.21至0.51])。卡博替尼组负相关OS更长(20.一个月VS12.一个月,风险比,0.54[95%CI,0.34至0.84])、ORR 高些(17%VS0%)。卡博替尼组人体骨骼有关(过虑词)发病率为23%,依维莫司组29%,依照单独的放射学联合会判断的骨扫描减轻率各自为20%和10%。卡博替尼组PFS、OS和ORR在沒有骨转移的情况蔓延的病患者中也有改进。卡博替尼组骨生物标志物的转变比依维莫司组大。在有骨转移的情况蔓延的病患者中,卡博替尼组和依维莫司组总的安全性性能与无骨转移的情况蔓延的病患者观查結果一致。结果在晚中后期肾细胞癌骨转移的情况蔓延病患者中,与依维莫司医治对比,卡博替尼的医治提升了无进度存活時间(PFS)、总存活時间(OS)和客观缓解率(ORR),说明对这种病患者而言是一种出色的诊治挑选。《壹篇》白红松

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial

https://doi.org/10.1200/JCO.2017.74.7352PurposeCabozantinib, an inhibitor of tyrosine kinases including MET, vascular endothelial growth factor receptors, and AXL, increased progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with advanced renal cell carcinoma (RCC) after previous vascular endothelial growth factor receptor–targeted therapy in the phase III METEOR trial. Because bone metastases are associated with increased morbidity in patients with RCC, bone-related outcomes were analyzed in METEOR.Patients and MethodsSix hundred fifty-eight patients were randomly assigned 1:1 to receive 60 mg cabozantinib or 10 mg everolimus. Prespecified subgroup analyses of PFS, OS, and ORR were conducted in patients grouped by baseline bone metastases status per independent radiology committee (IRC). Additional end points included bone scan response per IRC, skeletal-related events, and changes in bone biomarkers.ResultsFor patients with bone metastases at baseline (cabozantinib [n = 77]; everolimus [n = 65]), median PFS was 7.4 months for cabozantinib versus 2.7 months for everolimus (hazard ratio, 0.33 [95% CI, 0.21 to 0.51]). Median OS was also longer with cabozantinib (20.1 months v 12.1 months; hazard ratio, 0.54 [95% CI, 0.34 to 0.84]), and ORR per IRC was higher (17% v 0%). The rate of skeletal-related events was 23% with cabozantinib and 29% with everolimus, and bone scan response per IRC was 20% versus 10%, respectively. PFS, OS, and ORR were also improved with cabozantinib in patients without bone metastases. Changes in bone biomarkers were greater with cabozantinib than with everolimus. The overall safety profiles of cabozantinib and everolimus in patients with bone metastases were consistent with those observed in patients without bone metastases.ConclusionCabozantinib treatment was associated with improved PFS, OS, and ORR when compared with everolimus treatment in patients with advanced RCC and bone metastases and represents a good treatment option for these patients.《壹篇》(与桓兴医讯同歩)系关键朝向医护人员的服务性【微信号码:yaodaoyaofang】,不因盈利为目地,不开展一切有偿服务资询和服务项目,不销售一切商品,与ASCO、CSCO等全部技术专业学好和组织并没有任何的关联和联络,都不意味着一切官方网学好发音。文章照片均来源于互联网,不做商业行为,若有著作权异议请与《壹篇》联络。不断关注点赞——【手机微信:india2080】、称赞和分享——【手机微信:india2080】是一种心态和适用。
药道全世界,助推性命。印度的全世界海淘药店:珠穆朗玛峰卡博替尼照片。

weinxin
我的微信
这是我的微信扫一扫

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: